Midatech Group and MonoSol Rx Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies
Potential to Develop New Oral Drug Candidates with Superior Efficacy, Safety, Convenience, and Commercial Potential
Advertisement
Midatech Group and MonoSol Rx announced a partnership to develop new drug formulations combining biocompatible nanoparticles and PharmFilm delivery technologies.
Under terms of the agreement, Midatech Ltd and MonoSol Rx will jointly research, develop and commercialize new drug candidates designed to deliver therapeutic nanoparticles in thin film. Research and development will occur at Midatech Biogune S.L., in Bilbao, Spain with clinical development at a new facility in Basel, Switzerland. MonoSol Rx’s facility in Portage, Indiana is critical in these joint activities. Further terms were not disclosed.